Evolent Health, Inc. (NYSE:EVH) Receives $26.18 Consensus Price Target from Brokerages

Evolent Health, Inc. (NYSE:EVH) has earned an average recommendation of “Buy” from the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $26.18.

A number of research firms recently issued reports on EVH. KeyCorp started coverage on shares of Evolent Health in a report on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective for the company. BTIG Research lowered their price target on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, December 3rd. Stephens lowered Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $38.00 to $16.00 in a report on Friday, November 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a research report on Tuesday, November 12th. Finally, Barclays decreased their price objective on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, November 11th.

Evolent Health Trading Down 1.9 %

Shares of Evolent Health stock opened at $11.13 on Thursday. The firm has a market cap of $1.30 billion, a PE ratio of -12.23 and a beta of 1.45. Evolent Health has a 1 year low of $10.53 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The stock has a fifty day moving average price of $15.20 and a 200-day moving average price of $21.75.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in Evolent Health in the 2nd quarter valued at $32,000. Covestor Ltd increased its stake in Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after acquiring an additional 1,556 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Evolent Health during the 2nd quarter valued at about $61,000. Finally, Quest Partners LLC purchased a new position in shares of Evolent Health during the second quarter worth about $87,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.